Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.42 USD | +1.10% | +4.17% | +4.34% |
05-06 | Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating | MT |
05-02 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.34% | 12.55B | |
+17.73% | 47.02B | |
+48.77% | 41.86B | |
+0.86% | 41.76B | |
-4.27% | 28.8B | |
+11.48% | 26.05B | |
-21.25% | 19.15B | |
+28.51% | 12.34B | |
-4.40% | 11.82B | |
+20.36% | 11.8B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Bio-Techne Says European Union IVDR Certification Received for Diagnostic Test Tracking Chronic Myeloid Leukemia